Transition Assistance. Astellas shall provide the following transitional assistance, at its own cost unless specifically set forth below.

Transition Period. During the period of time (the “Transition Period”) commencing on the Officer End Date and ending on the Separation Date, Executive shall continue to be employed by the Company on a full time basis and provide such services as deemed necessary by the Company in Executive’s areas of expertise and work experience and responsibility.

Transition; Cooperation. Each of the Company and Executive shall use their respective reasonable efforts to cooperate with each other in good faith to facilitate a smooth transition of Executive’s duties to other executive(s) of the Company. After the Separation Date, Executive shall cooperate with the Company and its affiliates, upon the Company’s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Executive’s duties and responsibilities to the Company or its affiliates during his employment with the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s reasonable request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Executive’s possession during his employment); provided, however, that any such request by the Company shall not be unduly burdensome or interfere with Executive’s personal schedule or ability to engage in gainful employment.

Transition Period. As of the Effective Date, the Employee shall remain in the position of Chief Financial Officer (“CFO”) of the Company and will serve in that role until the Separation Date (such period, the “Transition Period”) unless earlier terminated in accordance with this Agreement. Effective as of the Separation Date, the Employee’s employment with the Company shall terminate.

Transition Plan. To facilitate Licensee’s Development obligations as contemplated hereunder, the Parties have agreed to a transition plan, attached as [Schedule 3.2.1] (the “Transition Plan”). The Transition Plan may be amended from time to time on mutual written agreement of the Parties. Licensee is responsible for such costs as identified in the Transition Plan.

Transition Assistance. Upon [[Aravive:Organization]]’s reasonable request, # [[3D Medicines:Organization]] shall provide such assistance as may be reasonably necessary or useful for [[Aravive:Organization]] to continue the Development and Commercialization of Licensed Products in the [[3D Medicines:Organization]] Territory, to the extent [[3D Medicines:Organization]] or its Affiliate is then performing or having performed such activities, including upon the reasonable request of [[Aravive:Organization]], assigning (to the extent [[3D Medicines:Organization]] has rights to assign) or using Commercially Reasonable Efforts to amend as appropriate any agreements or arrangements [[3D Medicines:Organization]] or its Affiliate have with any Third Party for the Development, distribution, sale or otherwise Commercialization of Licensed Products; and # [[3D Medicines:Organization]] shall provide [[Aravive:Organization]] with copies of any promotional and marketing materials generated by or on behalf of [[3D Medicines:Organization]] with respect to Licensed Products prior to the effective date of termination. If this Agreement is terminated by [[3D Medicines:Organization]] pursuant to [Sections 13.4, 13.5 or 15.6]6]6], [[Aravive:Organization]] shall bear all costs arising out of any of the transition assistance activities set forth in clause (i) or (ii) performed by [[3D Medicines:Organization]]. If this Agreement is terminated by [[3D Medicines:Organization]] pursuant to [Section 13.2] or by [[Aravive:Organization]] pursuant to Sections 13.3, 13.4, 13.5 or 15.6, [[3D Medicines:Organization]] shall bear all costs arising out of any of the transition assistance activities set forth in clause (i) or (ii) performed by [[3D Medicines:Organization]].

Transition Pay. The Company will continue to pay [[Person A:Person]] his regular salary through September 30, 2022 (at the same rate as in effect on the date of execution of this Agreement), irrespective of whether the Board accelerates the termination of [[Person A:Person]]’s employment to a date prior to September 30, 2022.

Prior to the Closing, Seller shall provide Purchaser and its officers, directors, employees, and consultants reasonable access, upon reasonable notice, to the Premises to begin planning for a transition of the Purchased Assets to Purchaser, including allowing Purchaser to use available storage space at the Premises and allowing Purchaser to begin installing racking at the Premises, in each case in a manner that does not disrupt Seller’s operation of the Business prior to the Closing. In the event that the Agreement is terminated, Purchaser shall promptly remove (at Purchaser’s sole cost and expense) any racking that it has installed. Purchaser shall be responsible for repairing any damage incurred in connection with its installation of racking at the Premises (or the removal of such racking in the event that this Agreement is terminated) and shall fully indemnify Seller (without limitation as to amount) for Losses relating to any such damage.

Transition Assistance. During the 90 days after a Termination Notice has been given, you will take all actions the Company may reasonably request to maintain for the Company the business, goodwill and business relationships with any Clients.

Transition Period. From the Effective Date until the first anniversary thereof, Dangel shall perform transition services as requested by the Company’s Board or its Chief Executive Officer. Without limiting the foregoing, during such one-year period, Dangel shall cooperate with the Company in the transition of his responsibilities to other officers and shall undertake all actions in connection therewith reasonably requested by the Company. The Parties agree that such services shall be nominal and primarily require information exchanges, introductions to third parties and responses to other requests that can generally be handled remotely by Dangel. Dangel agrees and covenants that, he shall, to the extent reasonably requested in writing by the Company, cooperate in good faith with and assist the Company in the pursuit or defense of any claim, administrative charge, or cause of action by or against the Company or any of its subsidiaries or affiliates as to which Dangel, by virtue of his employment with the Company, has relevant knowledge or information, including by acting as the Company’s representative in any such proceeding and, without the necessity of a subpoena, providing truthful testimony in any jurisdiction or forum. The Company shall reimburse Dangel for his reasonable out-of-pocket expenses in complying with this Section.